GLP-3: The Next Generation
GLP-3 refers to retatrutide, an investigational triple-agonist that represents the most advanced weight loss medication in development.
What Makes GLP-3 Different
- Triple Mechanism: Targets GLP-1 + GIP + glucagon receptors simultaneously
- 30%+ Weight Loss: Highest weight reduction ever observed in clinical trials
- Increased Energy Expenditure: Glucagon activation burns more calories at rest
- Enhanced Fat Oxidation: Your body preferentially burns fat for fuel
Clinical Results
Phase 2 data published in the New England Journal of Medicine showed 24.2% average body weight loss at 48 weeks — surpassing all existing medications.